Trial
NCT02720185
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
National Cancer Institute (NCI)
Condition
Breast Neoplasms
Intervention
Dasatinib
Why stopped
Study terminated early due to COVID-19 related slow enrollment and funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-03